Management of Autosomal Dominant Hypocalcemia Type 1: Literature Review and Clinical Practice Recommendations

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2024 Nov 28

PMID 39607645

Authors

Thomas De Coster

Karel David

Jeroen Breckpot

Brigitte Decallonne

Affiliations

Soon will be listed here.

Abstract

Purpose: Autosomal Dominant Hypocalcemia type 1 (ADH1), caused by gain-of-function variants in the calcium-sensing receptor (CASR), is characterized by a variable degree of hypocalcemia and hypercalciuria with inappropriately low PTH. The clinical spectrum is broad, ranging from being asymptomatic to presenting with severe clinical features of hypocalcemia and end-organ damage such as nephrolithiasis and intracerebral calcifications. Although the underlying pathophysiology is different, ADH1 patients are often managed as patients with 'classical' primary hypoparathyroidism, possibly leading to (exacerbation of) hypercalciuria. New treatments such as PTH analogues and calcilytics directly targeting the CASR are in the pipeline. Specific clinical guidance for treatment and monitoring of ADH1 patients is lacking. The purpose of this study is to provide a literature review on management of ADH1, including new therapies, and to formulate practice recommendations.

Methods: We searched for articles and ongoing clinical trials regarding management of ADH1.

Results: Forty articles were included. First we review the conventional treatment of ADH1, focusing on active vitamin D, calcium supplements, thiazide diuretics, phosphorus binders and dietary recommendations. In a second part we give an overview of studies with emerging treatments in ADH1: PTH analogues (PTH1-34, rhPTH1-84, TransCon PTH and others) and calcilytics (preclinical studies and clinical trials). In a third part we discuss literature findings regarding monitoring of ADH1 patients. Finally, we formulate clinical practice recommendations.

Conclusion: We provide an overview of conventional and new treatments for ADH1 patients. Based on these data, we propose practical recommendations to assist clinicians in the management of ADH1 patients.

References

Dershem R, Gorvin C, Metpally R, Krishnamurthy S, Smelser D, Hannan F . Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population. Am J Hum Genet. 2020; 106(6):734-747. PMC: 7273533. DOI: 10.1016/j.ajhg.2020.04.006. View

Nemeth E, Goodman W . Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures. Calcif Tissue Int. 2015; 98(4):341-58. DOI: 10.1007/s00223-015-0052-z. View

Hannan F, Kallay E, Chang W, Brandi M, Thakker R . The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018; 15(1):33-51. PMC: 6535143. DOI: 10.1038/s41574-018-0115-0. View

Brown E . Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab. 2013; 27(3):333-43. DOI: 10.1016/j.beem.2013.02.006. View

Matikainen N, Pekkarinen T, Ryhanen E, Schalin-Jantti C . Physiology of Calcium Homeostasis: An Overview. Endocrinol Metab Clin North Am. 2021; 50(4):575-590. DOI: 10.1016/j.ecl.2021.07.005. View

Hannan F, Nesbit M, Zhang C, Cranston T, Curley A, Harding B . Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012; 21(12):2768-78. DOI: 10.1093/hmg/dds105. View

Gorvin C . Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol. 2019; 63(2):R1-R16. DOI: 10.1530/JME-19-0104. View

Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M . Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002; 13(9):2259-66. DOI: 10.1097/01.asn.0000025781.16723.68. View

Egbuna O, Brown E . Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol. 2008; 22(1):129-48. PMC: 2364635. DOI: 10.1016/j.berh.2007.11.006. View

10.

Mrad F, Soares S, de Menezes Silva L, Dos Anjos Menezes P, Simoes-E-Silva A . Bartter's syndrome: clinical findings, genetic causes and therapeutic approach. World J Pediatr. 2020; 17(1):31-39. DOI: 10.1007/s12519-020-00370-4. View

11.

Mayr B, Schnabel D, Dorr H, Schofl C . GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts. Eur J Endocrinol. 2015; 174(5):R189-208. DOI: 10.1530/EJE-15-1028. View

12.

Thim S, Birkebaek N, Nissen P, Host C . Activating calcium-sensing receptor gene variants in children: a case study of infant hypocalcaemia and literature review. Acta Paediatr. 2014; 103(11):1117-25. DOI: 10.1111/apa.12743. View

13.

Pidasheva S, DSouza-Li L, Canaff L, Cole D, Hendy G . CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2004; 24(2):107-11. DOI: 10.1002/humu.20067. View

14.

David K, Moyson C, Vanderschueren D, Decallonne B . Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study. Eur J Endocrinol. 2018; 180(1):71-78. DOI: 10.1530/EJE-18-0580. View

15.

Saponaro F, Alfi G, Cetani F, Matrone A, Mazoni L, Apicella M . Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2022; 45(10):1909-1918. PMC: 9463210. DOI: 10.1007/s40618-022-01822-6. View

16.

Zavatta G, Tebben P, McCollough C, Yu L, Vrieze T, Clarke B . Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2021; 106(7):1900-1917. DOI: 10.1210/clinem/dgab162. View

17.

Aggarwal S, Kailash S, Sagar R, Tripathi M, Sreenivas V, Sharma R . Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013; 168(6):895-903. DOI: 10.1530/EJE-12-0946. View

18.

Kamarthi N, Venkatraman S, Patil P . Dental findings in the diagnosis of idiopathic hypoparathyroidism. Ann Saudi Med. 2013; 33(4):411-3. PMC: 6078510. DOI: 10.5144/0256-4947.2013.411. View

19.

Guarnieri V, DElia A, Baorda F, Pazienza V, Benegiamo G, Stanziale P . CASR gene activating mutations in two families with autosomal dominant hypocalcemia. Mol Genet Metab. 2012; 107(3):548-52. DOI: 10.1016/j.ymgme.2012.06.012. View

20.

Hannan F, Babinsky V, Thakker R . Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016; 57(3):R127-42. PMC: 5064759. DOI: 10.1530/JME-16-0124. View